The Myeloma Beacon Dr. Katja Weisel from the University Hospital in Tübingen, Germany, presented updated results from a Phase 3 study comparing the efficacy and safety of Pomalyst (pomalidomide) in combination with low-dose dexamethasone (Decadron) versus treatment ...
Cancer Network CHICAGO—Pomalidomide in combination with low-dose dexamethasone had a highly significant benefit on progression-free survival and overall survival compared with single-agent high-dose dexamethasone in patients with relapsed or refractory multiple ...
4-traders (press release) In the study, presented by Katja Weisel, M.D., Department of Medicine, University Hospital Tübingen, Tübingen, Germany, 455 patients were randomized to receive either pomalidomide plus low-dose dexamethasone (n=302) or high-dose dexamethasone ...
The Pharma Letter In the study, a total of 402 patients received four 28-day courses of lenalidomide and low-dose dexamethasone at diagnosis, and then were randomly assigned to receive six cycles of MPR (n=202) or MEL200 (n=200), and to receive either continuous ... and more »
